This is a really important aspect, since e.g., in the brain LAT1 is responsible for delivering EAA to neurons and glial cells and therefore, focusing on only the efficacy of LAT1 inhibition in the tumor microenvironment may neglect the possible central nervous system (CNS) side effects of the chemotherapy. The gene discussed is SLC7A5; the disease is neoplasm.